A new modality for immunosuppression: targeting the JAK/STAT pathway.
O'Shea
John J
JJ
Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. osheaj@arb.niams.nih.gov
Pesu
Marko
M
Borie
Dominic C
DC
Changelian
Paul S
PS
D000818:Animals; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000737:chemistry / Q000494:pharmacology*; D053631:Interleukin Receptor Common gamma Subunit; D053616:Janus Kinase 3; D015394:Molecular Structure; D009154:Mutation; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics; D020395:Receptors, Interleukin-7 / Q000235:genetics / Q000276:immunology*; D016511:Severe Combined Immunodeficiency / Q000188:drug therapy / Q000201:enzymology; D015398:Signal Transduction / Q000187:drug effects* / Q000276:immunology; D015534:Trans-Activators / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; C507941:IL2RG protein, human; D007166:Immunosuppressive Agents; D053631:Interleukin Receptor Common gamma Subunit; D020395:Receptors, Interleukin-7; D015534:Trans-Activators; D011505:Protein-Tyrosine Kinases; C507933:JAK3 protein, human; D053616:Janus Kinase 3